A detailed history of Clear Creek Financial Management, LLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Clear Creek Financial Management, LLC holds 138,525 shares of SAVA stock, worth $1.42 Million. This represents 0.36% of its overall portfolio holdings.

Number of Shares
138,525
Previous 134,605 2.91%
Holding current value
$1.42 Million
Previous $3.03 Million 7.23%
% of portfolio
0.36%
Previous 0.48%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 26, 2024

BUY
$18.44 - $26.41 $72,284 - $103,527
3,920 Added 2.91%
138,525 $2.81 Million
Q4 2023

Jan 23, 2024

BUY
$12.64 - $30.11 $382,549 - $911,279
30,265 Added 29.01%
134,605 $3.03 Million
Q3 2023

Oct 23, 2023

BUY
$16.64 - $25.32 $145,716 - $221,727
8,757 Added 9.16%
104,340 $1.74 Million
Q2 2023

Jul 14, 2023

SELL
$21.59 - $27.88 $52,010 - $67,162
-2,409 Reduced 2.46%
95,583 $2.34 Million
Q1 2023

Apr 20, 2023

BUY
$23.46 - $36.44 $720,738 - $1.12 Million
30,722 Added 45.67%
97,992 $2.36 Million
Q4 2022

Jan 23, 2023

BUY
$27.82 - $44.16 $1.43 Million - $2.27 Million
51,390 Added 323.61%
67,270 $0
Q3 2022

Oct 24, 2022

SELL
$16.33 - $51.06 $181,262 - $566,766
-11,100 Reduced 41.14%
15,880 $664,000
Q2 2022

Jul 27, 2022

BUY
$17.22 - $38.47 $192,003 - $428,940
11,150 Added 70.44%
26,980 $759,000
Q1 2022

May 02, 2022

BUY
$32.6 - $53.05 $164,630 - $267,902
5,050 Added 46.85%
15,830 $588,000
Q4 2021

Jan 21, 2022

BUY
$36.77 - $90.91 $208,669 - $515,914
5,675 Added 111.17%
10,780 $471,000
Q3 2021

Oct 14, 2021

BUY
$41.79 - $135.3 $213,337 - $690,706
5,105 New
5,105 $317,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $410M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Clear Creek Financial Management, LLC Portfolio

Follow Clear Creek Financial Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clear Creek Financial Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clear Creek Financial Management, LLC with notifications on news.